AU2001266124A1 - 2-aminothiazoline derivatives and their use as no-synthase inhibitors - Google Patents

2-aminothiazoline derivatives and their use as no-synthase inhibitors

Info

Publication number
AU2001266124A1
AU2001266124A1 AU2001266124A AU6612401A AU2001266124A1 AU 2001266124 A1 AU2001266124 A1 AU 2001266124A1 AU 2001266124 A AU2001266124 A AU 2001266124A AU 6612401 A AU6612401 A AU 6612401A AU 2001266124 A1 AU2001266124 A1 AU 2001266124A1
Authority
AU
Australia
Prior art keywords
synthase inhibitors
aminothiazoline
derivatives
aminothiazoline derivatives
synthase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266124A
Other languages
English (en)
Inventor
Eric Bacque
Antony Bigot
Jean-Christophe Carry
Dominique Damour
Claude Guyon
Serge Mignani
Michel Tabart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU2001266124A1 publication Critical patent/AU2001266124A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AU2001266124A 2000-06-09 2001-06-07 2-aminothiazoline derivatives and their use as no-synthase inhibitors Abandoned AU2001266124A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0007397 2000-06-09
FR0007397A FR2810037B1 (fr) 2000-06-09 2000-06-09 Utilisation de derives de 2-aminothiazoline comme inhibiteurs de no-synthase inductible
PCT/FR2001/001760 WO2001094325A1 (fr) 2000-06-09 2001-06-07 Derives de 2-aminothiazoline et leur utilisation comme inhibiteurs de no-synthase

Publications (1)

Publication Number Publication Date
AU2001266124A1 true AU2001266124A1 (en) 2001-12-17

Family

ID=8851134

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266124A Abandoned AU2001266124A1 (en) 2000-06-09 2001-06-07 2-aminothiazoline derivatives and their use as no-synthase inhibitors

Country Status (29)

Country Link
EP (1) EP1299365B1 (pt)
JP (1) JP4238026B2 (pt)
KR (1) KR20030025931A (pt)
CN (1) CN1202096C (pt)
AP (1) AP2002002708A0 (pt)
AR (1) AR029937A1 (pt)
AT (1) ATE305460T1 (pt)
AU (1) AU2001266124A1 (pt)
BR (1) BR0111986A (pt)
CA (1) CA2411760C (pt)
DE (1) DE60113689T2 (pt)
DK (1) DK1299365T3 (pt)
DZ (1) DZ3367A1 (pt)
EA (1) EA200300010A1 (pt)
EC (1) ECSP024375A (pt)
ES (1) ES2248347T3 (pt)
FR (1) FR2810037B1 (pt)
HK (1) HK1057900A1 (pt)
HR (1) HRP20020970A2 (pt)
HU (1) HUP0301000A2 (pt)
IL (1) IL153328A0 (pt)
MA (1) MA25814A1 (pt)
MX (1) MXPA02012071A (pt)
NO (1) NO20025884L (pt)
NZ (1) NZ522968A (pt)
OA (1) OA12286A (pt)
PL (1) PL360285A1 (pt)
WO (1) WO2001094325A1 (pt)
ZA (1) ZA200209769B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2337654T3 (es) * 2001-09-26 2010-04-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Esfingolipidos.
PT1450750E (pt) * 2001-11-09 2010-01-18 Aventis Pharma Sa Derivados de 2-amino-4-piridilmetil-tiazolina e sua utilização como inibidores da no-sintase induzível
MXPA04003695A (es) * 2001-11-09 2004-07-30 Aventis Pharma Sa Derivados de 2-amino-tiazolina y su uso como inhibidores de no-sintasa inducible.
EP1446402B1 (fr) * 2001-11-09 2005-11-02 Aventis Pharma S.A. Derives de 2-amino-4-heteroarylethyl thiazoline et leur utilisation comme inhibiteurs de no-synthase inductible
WO2003075922A1 (fr) * 2002-03-14 2003-09-18 Dainippon Pharmaceutical Co., Ltd. Inhibiteurs de la synthetase du monoxyde d'azote
CA2494323C (en) 2002-08-07 2011-01-25 Neuraxon Inc. Amino benzothiazole compounds with nos inhibitory activity
DE10332560B4 (de) * 2003-07-11 2010-07-08 Chiracon Gmbh Verfahren zur Herstellung von ß- Heteroaryl-2-alanin-Verbindungen über 2-Amino-2-(heteroarylmethyl)-carbonsäure-Verbindungen
KR101800507B1 (ko) 2015-09-18 2018-01-18 주식회사 이엔이티아이 자동세척 스크린과 식물정화장치를 활용하여 지속적으로 유입되는 생활하수나 공정폐수가 유입되는 오염하천정화를 위한 방법 및 그 장치

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066662A (en) * 1990-05-21 1991-11-19 Warner-Lambert Company Substituted oxazolidin-2-ones and 1,2,4-oxadiazolin-5-ones and derivatives thereof acting at muscarinic receptors
AU5533094A (en) * 1992-11-27 1994-06-22 Wellcome Foundation Limited, The Enzyme inhibitors
JPH09504028A (ja) * 1993-10-21 1997-04-22 ジー．ディー．サール アンド カンパニー 酸化窒素シンターゼ抑制剤として有用なアミジノ誘導体
WO1996014842A1 (en) * 1994-11-15 1996-05-23 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase
DE60018216T2 (de) * 1999-12-24 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Kondensierte purinderivate

Also Published As

Publication number Publication date
NZ522968A (en) 2005-07-29
ES2248347T3 (es) 2006-03-16
NO20025884D0 (no) 2002-12-06
ZA200209769B (en) 2004-03-02
MXPA02012071A (es) 2004-09-10
EP1299365B1 (fr) 2005-09-28
PL360285A1 (en) 2004-09-06
EP1299365A1 (fr) 2003-04-09
AR029937A1 (es) 2003-07-23
DZ3367A1 (fr) 2001-12-13
FR2810037B1 (fr) 2004-04-23
IL153328A0 (en) 2003-07-06
CA2411760C (fr) 2009-12-29
HK1057900A1 (en) 2004-04-23
JP2003535853A (ja) 2003-12-02
BR0111986A (pt) 2003-04-01
EA200300010A1 (ru) 2003-06-26
DK1299365T3 (da) 2006-02-06
CN1444572A (zh) 2003-09-24
DE60113689T2 (de) 2006-07-13
KR20030025931A (ko) 2003-03-29
MA25814A1 (fr) 2003-07-01
ECSP024375A (es) 2003-02-06
FR2810037A1 (fr) 2001-12-14
DE60113689D1 (de) 2006-02-09
CN1202096C (zh) 2005-05-18
JP4238026B2 (ja) 2009-03-11
WO2001094325A1 (fr) 2001-12-13
ATE305460T1 (de) 2005-10-15
HUP0301000A2 (hu) 2003-08-28
OA12286A (en) 2006-05-12
HRP20020970A2 (en) 2005-02-28
NO20025884L (no) 2003-01-29
CA2411760A1 (fr) 2001-12-13
AP2002002708A0 (en) 2002-12-31

Similar Documents

Publication Publication Date Title
IL152078A0 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU2002226486A1 (en) Novel c-glycoside derivatives and use thereof
SI1686119T1 (sl) Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
AU2001244399A1 (en) Gamma-secretase inhibitors
AU2001240542A1 (en) Heterocyclic compounds and their use as parp inhibitors
HK1053124A1 (en) Substituted quinazoline derivatives and their use as inhibitors
AU2001258771A1 (en) -secretase inhibitors
HK1057214A1 (en) New mandelic acid derivatives and their use as throbin inhibitors
AU2002226487A1 (en) Novel c-glycoside derivatives and use thereof
HUP0203961A3 (en) 3-phenoxy-1-phenyl acetylene derivatives and their use as herbicedes
AU2002230836A1 (en) Benzylamine derivatives and their use as thrombin inhibitors
AU2001281799A1 (en) Benzamide derivatives and their use as apob-100 and mtp inhibitors
AU2001244596A1 (en) Indolylpyrrole derivatives and cell death inhibitors
AU2001276027A1 (en) Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors
IL152396A0 (en) New thiochromane derivatives derivatives and their use as thrombin inhibitors
AU2002216650A1 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
AU4501199A (en) 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
AU2001266124A1 (en) 2-aminothiazoline derivatives and their use as no-synthase inhibitors
AU2001277561A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU4432001A (en) Trityl-type compounds and their use
AU2001259626A1 (en) Indole derivatives and their use as 15-lipoxygenase inhibitors
AU2001235364A1 (en) Tetrahydronaphtalene derivatives and their use
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application